These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 29094604)

  • 1. Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials.
    Wu B; Lin H; Tobe RG; Zhang L; He B
    J Comp Eff Res; 2018 Mar; 7(3):281-291. PubMed ID: 29094604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
    Li J; Wang Q; Wu C; Qu X; Zhang L; He X; Ma S; Qiu M; Wang X
    Cardiology; 2023; 148(4):363-373. PubMed ID: 37094558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: Systematic review and meta-analysis.
    Misumida N; Aoi S; Kim SM; Ziada KM; Abdel-Latif A
    Cardiovasc Revasc Med; 2018 Sep; 19(6):689-694. PubMed ID: 29452843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Ticagrelor in East Asian Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
    Xie C; Lin J; Qin Q; Zhu J
    Anatol J Cardiol; 2022 Jun; 26(6):434-441. PubMed ID: 35703479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Ticagrelor With Clopidogrel in East Asian Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Ma Y; Zhong PY; Shang YS; Bai N; Niu Y; Wang ZL
    J Cardiovasc Pharmacol; 2022 May; 79(5):632-640. PubMed ID: 35091511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Clopidogrel vs. Ticagrelor in Dual Antiplatelet Therapy Regimens for High-Bleeding Risk Acute Coronary Syndrome Patients: A Comprehensive Meta-analysis of Adverse Outcomes.
    Khalid AR; Ahmad F; Naeem MAB; Ahmed S; Umar M; Mehmood H; Kashif M; Ali S
    High Blood Press Cardiovasc Prev; 2024 Mar; 31(2):141-155. PubMed ID: 38557855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Potent Oral P2Y
    Ma S; Li Z; Yu P; Song H; Jiang Z; Li Y; Han Y
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):199-208. PubMed ID: 32006144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome.
    Spoendlin J; Gagne JJ; Lewey JJ; Patorno E; Schneeweiss S; Desai RJ
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1361-1370. PubMed ID: 30379372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis.
    Guo Y; Ge P; Li Z; Xiao J; Xie L
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):533-546. PubMed ID: 37530990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of low dose ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis.
    Chen Q; Zhang Y; Wang Z; Wang S; Zhang H; Wang Y; Lu C; Xuan H; Wang C; Li D; Xu T
    Postgrad Med J; 2020 Nov; 96(1141):693-702. PubMed ID: 32561595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
    Ueland T; Åkerblom A; Ghukasyan T; Michelsen AE; Aukrust P; Becker RC; Bertilsson M; Himmelmann A; James SK; Siegbahn A; Storey RF; Kontny F; Wallentin L;
    J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29330256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.
    Zhuo X; Zhuo B; Ouyang S; Niu P; Xiao M
    BMC Pharmacol Toxicol; 2018 Sep; 19(1):54. PubMed ID: 30176938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy assessment of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention by data mining and machine-learning decision tree approaches.
    Xue Y; Hu Z; Jing Y; Wu H; Li X; Wang J; Seybert A; Xie X; Lv Q
    J Clin Pharm Ther; 2020 Oct; 45(5):1076-1086. PubMed ID: 32627223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention.
    Wang C; Zheng W; Shaqdan A; Wang C; Qin X; Zhao X; Wang X; Yuan L; Nie S; Liu R
    Platelets; 2020; 31(3):337-343. PubMed ID: 31043110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
    Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
    EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
    Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
    Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials.
    Kheiri B; Osman M; Abdalla A; Haykal T; Barbarawi M; Zayed Y; Hicks M; Ahmed S; Bachuwa G; Hassan M; Bhatt DL
    J Thromb Thrombolysis; 2018 Oct; 46(3):299-303. PubMed ID: 29934940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    You SC; Rho Y; Bikdeli B; Kim J; Siapos A; Weaver J; Londhe A; Cho J; Park J; Schuemie M; Suchard MA; Madigan D; Hripcsak G; Gupta A; Reich CG; Ryan PB; Park RW; Krumholz HM
    JAMA; 2020 Oct; 324(16):1640-1650. PubMed ID: 33107944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study).
    Liu GZ; Zhang S; Sun DH; Shi J; Bo WL; Wang WN; Zhang CY; Wang ZH; Feng W; He MJ; Liu YY; Li S; Zheng LQ; Li Y
    Eur J Clin Pharmacol; 2019 Aug; 75(8):1059-1068. PubMed ID: 31081522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Ticagrelor Compared with Clopidogrel in Patients with End-Stage Renal Disease with Acute Myocardial Infarction.
    Lee CH; Tsai TH; Lin CJ; Hsueh SK; Chung WJ; Cheng CI
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):325-334. PubMed ID: 30746615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.